Asensus Surgical Inc logo

Asensus Surgical Inc

1
AMEX:ASXC (USA)   Ordinary Shares
$ 0.33 +0.0972 (+41.4%) 04:00 PM EST
At Loss
P/B:
6.64
Market Cap:
$ 90.41M
Enterprise V:
$ 61.41M
Volume:
36.02M
Avg Vol (2M):
1.11M
Also Trade In:
Volume:
36.02M
At Loss
Avg Vol (2M):
1.11M
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Asensus Surgical Inc ( ) from 1991 to Jun 07 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Asensus Surgical stock (ASXC) PE ratio as of Jun 07 2024 is 0. More Details

Asensus Surgical Inc (ASXC) PE Ratio (TTM) Chart

To

Asensus Surgical Inc (ASXC) PE Ratio (TTM) Historical Data

Total 1245
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Asensus Surgical PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-06-07 At Loss 2024-04-04 At Loss
2024-06-06 At Loss 2024-04-03 At Loss
2024-06-05 At Loss 2024-04-02 At Loss
2024-06-04 At Loss 2024-04-01 At Loss
2024-06-03 At Loss 2024-03-28 At Loss
2024-05-31 At Loss 2024-03-27 At Loss
2024-05-30 At Loss 2024-03-26 At Loss
2024-05-29 At Loss 2024-03-25 At Loss
2024-05-28 At Loss 2024-03-22 At Loss
2024-05-24 At Loss 2024-03-21 At Loss
2024-05-23 At Loss 2024-03-20 At Loss
2024-05-22 At Loss 2024-03-19 At Loss
2024-05-21 At Loss 2024-03-18 At Loss
2024-05-20 At Loss 2024-03-15 At Loss
2024-05-17 At Loss 2024-03-14 At Loss
2024-05-16 At Loss 2024-03-13 At Loss
2024-05-15 At Loss 2024-03-12 At Loss
2024-05-14 At Loss 2024-03-11 At Loss
2024-05-13 At Loss 2024-03-08 At Loss
2024-05-10 At Loss 2024-03-07 At Loss
2024-05-09 At Loss 2024-03-06 At Loss
2024-05-08 At Loss 2024-03-05 At Loss
2024-05-07 At Loss 2024-03-04 At Loss
2024-05-06 At Loss 2024-03-01 At Loss
2024-05-03 At Loss 2024-02-29 At Loss
2024-05-02 At Loss 2024-02-28 At Loss
2024-05-01 At Loss 2024-02-27 At Loss
2024-04-30 At Loss 2024-02-26 At Loss
2024-04-29 At Loss 2024-02-23 At Loss
2024-04-26 At Loss 2024-02-22 At Loss
2024-04-25 At Loss 2024-02-21 At Loss
2024-04-24 At Loss 2024-02-20 At Loss
2024-04-23 At Loss 2024-02-16 At Loss
2024-04-22 At Loss 2024-02-15 At Loss
2024-04-19 At Loss 2024-02-14 At Loss
2024-04-18 At Loss 2024-02-13 At Loss
2024-04-17 At Loss 2024-02-12 At Loss
2024-04-16 At Loss 2024-02-09 At Loss
2024-04-15 At Loss 2024-02-08 At Loss
2024-04-12 At Loss 2024-02-07 At Loss
2024-04-11 At Loss 2024-02-06 At Loss
2024-04-10 At Loss 2024-02-05 At Loss
2024-04-09 At Loss 2024-02-02 At Loss
2024-04-08 At Loss 2024-02-01 At Loss
2024-04-05 At Loss 2024-01-31 At Loss

Asensus Surgical Inc (ASXC) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Asensus Surgical Inc logo
Asensus Surgical Inc
NAICS : 339112 SIC : 3841
ISIN : US89366M2017

Share Class Description:

ASXC: Ordinary Shares
Description
Asensus Surgical Inc is a medical device company that digitizes the interface between the surgeon and the patient to improve minimally invasive surgery through digital laparoscopy. It enables the use of capabilities such as augmented intelligence, connectivity, and robotics in laparoscopy and seeks to address the current clinical, cognitive, and economic shortcomings in surgery. The Senhance Surgical System is the first machine vision system for use in robotic surgery, which is powered by the new Intelligent Surgical Unit that enables augmented intelligence in surgery and brings the benefits of digital laparoscopy to patients around the world. The company's single segment includes the research, development, and sale of medical device robotics to improve minimally invasive surgery.